دورية أكاديمية
The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study
| العنوان: | The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study |
|---|---|
| المؤلفون: | Hall, Lewis A., McKay, Siobhan C., Halle-Smith, James, Soane, Joshua, Osei-Bordom, Daniel-Clement, Goodburn, Lesley, Magill, Laura, Pinkney, Thomas, Radhakrishna, Ganesh, Valle, Juan W., Corrie, Pippa, Roberts, Keith J., Hughes, Terry, Perry, Rita, Walters, Michael, Acharya, Radhika, Binnersly, Thomas, Brown, Samuel J., Everitt, Rebecca, Hargreaves, Oscar, Hodgson, Samuel, Parylo, Jacek, Perrett, Madeleine, Smith, Daniel J., Thorne, Thomas, Abouelazayem, Mohamed, Bradley, Alison, Currow, Chelise, Fox, Richard, Giles, Benjamin, Kourdouli, Amar, Mahmood, Fahad, Moir, John, Mowbray, Nicholas, Shotton, Rohan, Vivekananthan, Cavitha, Zakeri, Roxanna, Abbadi, Reyad, Abbott, Sian, Abdelrahim, Hamza, Abukar, Yusria, Adel, Nader, Adwan, Hussamuddin, Ahmed, Marriam, Ahmed, Shehzad, Ahmed, Irfan, Akotat, Ouiam, Al-Sarireh, Bilal, Alamassi, Amro |
| المصدر: | British Journal of Cancer ; volume 128, issue 10, page 1922-1932 ; ISSN 0007-0920 1532-1827 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Cancer Research, Oncology |
| الوصف: | Introduction CONTACT is a national multidisciplinary study assessing the impact of the COVID-19 pandemic upon diagnostic and treatment pathways among patients with pancreatic ductal adenocarcinoma (PDAC). Methods The treatment of consecutive patients with newly diagnosed PDAC from a pre-COVID-19 pandemic cohort (07/01/2019-03/03/2019) were compared to a cohort diagnosed during the first wave of the UK pandemic (‘ COVID’ cohort, 16/03/2020-10/05/2020) , with 12-month follow-up. Results Among 984 patients (pre-COVID: n = 483, COVID: n = 501), the COVID cohort was less likely to receive staging investigations other than CT scanning (29.5% vs. 37.2%, p = 0.010). Among patients treated with curative intent, there was a reduction in the proportion of patients recommended surgery (54.5% vs. 76.6%, p = 0.001) and increase in the proportion recommended upfront chemotherapy (45.5% vs. 23.4%, p = 0.002). Among patients on a non-curative pathway, fewer patients were recommended (47.4% vs. 57.3%, p = 0.004) or received palliative anti-cancer therapy (20.5% vs. 26.5%, p = 0.045). Ultimately, fewer patients in the COVID cohort underwent surgical resection (6.4% vs. 9.3%, p = 0.036), whilst more patients received no anti-cancer treatment (69.3% vs. 59.2% p = 0.009). Despite these differences, there was no difference in median overall survival between the COVID and pre-COVID cohorts, (3.5 (IQR 2.8–4.1) vs. 4.4 (IQR 3.6–5.2) months, p = 0.093). Conclusion Pathways for patients with PDAC were significantly disrupted during the first wave of the COVID-19 pandemic, with fewer patients receiving standard treatments. However, no significant impact on survival was discerned. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1038/s41416-023-02220-2 |
| الإتاحة: | https://doi.org/10.1038/s41416-023-02220-2Test https://www.nature.com/articles/s41416-023-02220-2.pdfTest https://www.nature.com/articles/s41416-023-02220-2Test |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: | edsbas.45D84A58 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41416-023-02220-2 |
|---|